MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.

@article{Perry2014MYCAB,
  title={MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.},
  author={Anamarija M Perry and Yuridia L Alvarado-Bernal and Javier Ariel Laurini and Lynette M. Smith and Graham W Slack and King L Tan and Laurie H. Sehn and Kai Fu and Patricia A Aoun and Timothy C. Greiner and Wing Chung Chan and Philip Jay Bierman and Robert Gregory Bociek and James Olen Armitage and Julie Marie Vose and Randy D. Gascoyne and Dennis D. Weisenburger},
  journal={British journal of haematology},
  year={2014},
  volume={165 3},
  pages={382-91}
}
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease and "double-hit" DLBCL, with both MYC and BCL2 translocations has a poor prognosis. In this study, we investigated whether MYC and BCL2 protein expression in tissue would predict survival in DLBCL. The study included 106 cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or CHOP-like regimens. The results were validated on an independent cohort of 205 DLBCL patients… CONTINUE READING